Acumen Pharmaceuticals (ABOS) is scheduled to report Q4 earnings on March 26, 2026. Analysts estimate EPS of $-0.53 and quarterly revenue of N/A.
In the most recent quarter (Q3), Acumen Pharmaceuticals reported EPS of $-0.44, beating estimates of $-0.66 by 0.33%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.
Over the last 4 quarters, Acumen Pharmaceuticals has averaged an EPS surprise of 0.35% and a revenue surprise of 0.00%.
Analyze the earnings history of Acumen Pharmaceuticals using advanced sorting and filters.
The chart below shows Acumen Pharmaceuticals's reported EPS compared to analyst estimates over recent quarters.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-11-12 | $-0.44 | $-0.66 | 33.3 % |
| Q2 | 2025-08-12 | $-0.68 | $-0.53 | -28.3 % |
| Q1 | 2025-05-13 | $-0.48 | $-0.55 | 12.7 % |
| Q4 | 2025-03-27 | $-0.62 | $-0.37 | -67.6 % |
The chart below shows Acumen Pharmaceuticals's reported revenue compared to analyst estimates over recent quarters.
Acumen Pharmaceuticals (ABOS) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on November 12, 2025 for Q3.
The Actual EPS was $-0.44, which beat the estimate of $-0.66.
The Actual Revenue was $0.00, which hit the estimate of $0.00.